Connect with us

Hi, what are you looking for?

Wednesday, Jun 12, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Tilray expands portfolio in Italy, partners with cancer researchers

The company will be supporting the cancer and patient care conference ONCOWELLNESS

Tilray partners with Italian cancer researchers, launches 3 new medical cannabis products
Photo via Tilray

Leading Canadian cannabis producer Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) has received authorization from Italy’s Ministry of Health to distribute three new medical cannabis compounds in the country.

The company also announced Thursday it will be collaborating with Italian oncology researchers and supporting a cancer conference taking place this year.

The authorized medical cannabis compounds will be supplied by Tilray Medical to FL Group, its subsidiary, which will distribute them to pharmacies across Italy.

In addition to the authorization, Tilray also announced a new strategic partnership with Pharmaidea, a Petrone Group company. The partnership will focus on marketing and educating over 12,000 pharmacies across Italy on the benefits of medical cannabis and medical cannabis patient care.

Tilray Medical has an established broad national pharmaceutical distribution network in Italy, where medical cannabis is reimbursed by the healthcare system to eligible patients. Medical doctors in Italy can prescribe Tilray-supplied medical cannabis extracts at different concentrations throughout the country.

“We are extremely humbled by the trust that patients, health care providers and governments have placed in us and our medical cannabis products and take our responsibility very seriously,” Tilray CSO Denise Faltischek said in a statement.

“Our Tilray Medical team remains dedicated to patient advocacy and education across our international markets while providing quality, consistent medicinal cannabis for commercial, compassionate access, and research purposes.”

Read more: Tilray’s Solei brand launches cannabinoid-infused tea line

Read more: Tilray reports $1.1B in losses during Q3 2023, acquires Hexo for $75M

Tilray partners with cancer research community

The company also announced it will be collaborating with the oncology and patient care research community in Italy by supporting the cancer and patient care conference ONCOWELLNESS.

This conference is accredited by Italy’s Ministry of Health and is led by Dr. Vittorio A. Guardamagna, National Coordinator and Director of SC Pain Therapy and Palliative Care at the European Institute of Oncology (IEO) Milan.

It brings together top healthcare practitioners from various fields, including orthopedics, geriatrics, anesthesia, intensive care and psychiatry among other specialties.

Participants at the conference will have the opportunity to share their experiences in daily practice, discuss integrated and multidisciplinary therapeutic strategies, and deepen their understanding of clinical trial results and the introduction of therapy preparations based on medical cannabis.

The ONCOWELLNESS conference is scheduled to take place on May 27, 2023, in Milan on Sept. 9, 2023, at the Careggi Hospital in Florence, and on November 18, 2023, at the University Hospital UNIBA in Bari.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The Science of Smokeability study will be ongoing for the next two years


The 2024 amendment will jeopardize the multi-billion dollar hemp industry

AI and Autonomy

The American National Cancer Institute collaborated with Australian researchers to develop the deep learning model


Although both compounds are found in the cannabis plant, there are significant differences in their effects and legislation